Table 3: Major studies of plasma Aβ40 and Aβ42.

StudyYearFollowSubjectMarkerResultsJournal

Matsubara199936 AD
206 cont
6 DS
Lipoprotein free Aβ40, Aβ42Increased plasma lipoprotein free Aβ42 in AD and Down SyndromeAnn Neurol

Van Oijen20068.6 Y
Rotterdam
study
1,756/6,713Aβ40, Aβ42
Aβ42/Aβ40
396 cases developed dementia during follow up
Increased Aβ40 level was a risk for onset of dementia
Increased Aβ42/Aβ40 ratio decreased the risk for onset of dementia
Lancet Neurol

Graff-Radford20073.7 Y Mayo Cohort563 controlAβ40, Aβ42 Aβ42/Aβ4053 cases developed MCI and AD
Significantly increased risk for onset of MCI and AD (3.1) in lower 25% group with decreased Aβ42/Aβ40 ratio
Arch Neurol

Schupf20084.6 Y1,125 controlAβ40, Aβ42 Protofibrillar Aβ42104 cases developed AD (9.2%)
High Aβ42 level increased threefold risk for onset of AD
Once developing AD, plasma Aβ42, Aβ42/Aβ40 ratio and protofibrillar Aβ42 were significantly decreased
PNAS

Xu2008113 AD
205 control
Autoantibody Aβ40, Aβ42Anti-Aβ42 dimer antibody was absent in AD
Aβ40/42 ratio increase with progression of AD
Brain Res

Lambert20094 Y233 dementia
958 control
8,414 source
Aβ40, Aβ42prospective 3 city study
Aβ42/Aβ40 ratio showed short-term risk of dementia
Neurol

Okereke200910 Y prospective481 NursesAβ40, Aβ42Presenile (mean 64 Y) high Aβ42/ Aβ40 ratio correlated with cognitive function 10 years laterArch Neurol